Pulmonary Division, Faculty of Medicine, Université de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada.
J Immunol. 2010 Apr 1;184(7):3897-906. doi: 10.4049/jimmunol.0902958. Epub 2010 Mar 3.
Neutrophils influence innate and adaptative immunity by generating numerous mediators whose regulation largely depends on the IkappaB kinase (IKK)/IkappaB/NF-kappaB signaling cascade. A singular feature of neutrophils is that they express several components of this pathway (namely, NF-kappaB/Rel proteins and IkappaB-alpha) in both the nucleus and cytoplasm. We recently reported that the IKK complex of neutrophils is similarly expressed and activated in both cellular compartments. However, the upstream IKK kinase has not yet been identified. In this study, we report that neutrophils express the mitogen-activated protein 3 kinase, TGF-beta-activated kinase 1 (TAK1), as well as its associated partners, TAK1-binding protein (TAB) 1, TAB2, and TAB4, in both the cytoplasm and nucleus. Following cell stimulation by TNF-alpha or LPS, TAK1 becomes rapidly and transiently activated. Blocking TAK1 kinase activity with a highly selective inhibitor (5z-7-oxozeaenol) attenuated the phosphorylation of nuclear and cytoplasmic IKKalpha/beta, IkappaB-alpha, and RelA, and also impaired IkappaB-alpha degradation and NF-kappaB DNA binding in activated neutrophils. Moreover, TAK1 was found to be involved in the activation of p38 MAPK and ERK, which also influence cytokine generation in neutrophils. As a result, inflammatory cytokine expression and release were profoundly impaired following TAK1 inhibition. Similarly, the delayed apoptosis observed in response to LPS or TNF-alpha was reversed by TAK1 inhibition. By contrast, IKKgamma phosphorylation and STAT1 activation were unaffected by TAK1 inhibition. Our data establish the central role of TAK1 in controlling nuclear and cytoplasmic signaling cascades in primary neutrophils, making it a promising target for therapeutic intervention in view of the foremost role of neutrophils in several chronic inflammatory conditions.
中性粒细胞通过生成大量介质来影响先天免疫和适应性免疫,这些介质的调节在很大程度上依赖于 IkappaB 激酶 (IKK)/IkappaB/NF-kappaB 信号级联。中性粒细胞的一个显著特征是,它们在细胞核和细胞质中都表达这种途径的几个成分(即 NF-kappaB/Rel 蛋白和 IkappaB-alpha)。我们最近报道,中性粒细胞的 IKK 复合物在这两个细胞区室中同样表达并被激活。然而,上游的 IKK 激酶尚未被鉴定。在这项研究中,我们报告中性粒细胞在细胞质和细胞核中表达丝裂原激活的蛋白激酶 3(TGF-β激活激酶 1,TAK1)以及其相关的伴侣 TAK1 结合蛋白 (TAB) 1、TAB2 和 TAB4。在 TNF-α或 LPS 刺激细胞后,TAK1 迅速且短暂地被激活。用高度选择性抑制剂(5z-7-氧杂氮杂烯醇)阻断 TAK1 激酶活性减弱了核和细胞质 IKKalpha/beta、IkappaB-alpha 和 RelA 的磷酸化,也损害了激活的中性粒细胞中 IkappaB-alpha 的降解和 NF-kappaB DNA 结合。此外,发现 TAK1 参与 p38 MAPK 和 ERK 的激活,这也影响中性粒细胞中细胞因子的产生。因此,TAK1 抑制后炎症细胞因子的表达和释放受到严重损害。同样,TAK1 抑制逆转了 LPS 或 TNF-α 引起的延迟凋亡。相比之下,TAK1 抑制对 IKKgamma 磷酸化和 STAT1 激活没有影响。我们的数据确立了 TAK1 在控制原代中性粒细胞核内和细胞质信号级联中的核心作用,使其成为治疗干预的有前途的靶点,因为中性粒细胞在几种慢性炎症疾病中起着首要作用。